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ZrO2, and BaSO4) also do not report the occurrence of pro-
nounced treatment-related findings. Overall, the results of 
the present survey provide a first indication that the tested 
nanomaterials neither cause local nor systemic effects upon 
subacute oral administration under the selected experimen-
tal conditions. Further investigations should aim at eluci-
dating the extent of gastrointestinal absorption of surface-
functionalized nanomaterials.
Keywords Nanomaterial (NM) · Surface 
functionalization · Oral route of exposure · Subacute 
toxicity · OEcD test guideline 407 · Metabolomics
Introduction
Due to the well-known effects of generic particulate dusts 
on the human lung and its thin air–blood barrier, uptake 
by inhalation is expected to be the critical route of expo-
sure for most nanomaterials (NMs) (Hankin et al. 2011). 
In recognition thereof, information on in vitro and in vivo 
pulmonary effects of NMs is increasingly becoming avail-
able (landsiedel et al. 2012a). However, consumers might 
also be exposed to NMs orally, e.g., when they are taken 
up as additives to food products, upon release from food 
contact materials, or when they are contained in cosmetic 
articles, such as lipstick or toothpaste. Furthermore, NMs 
may be taken up orally, when they are used in the phar-
macological context, e.g., to increase oral drug bioavail-
ability or to promote applicability of drugs (Bouwmeester 
et al. 2011; Fröhlich and Roblegg 2012). Finally, also 
inhaled NMs may be translocated into the pharynx by the 
mucociliary clearance system of the respiratory tract and 
be swallowed into the gastrointestinal tract (landsiedel 
et al. 2012b).
Abstract The effects of seven nanomaterials (four amor-
phous silicon dioxides with or without surface function-
alization, two surface-functionalized zirconium dioxides, 
and barium sulfate) upon 28-day oral exposure to male or 
female rats were investigated. The studies were performed 
as limit tests in accordance with OEcD Test guideline 
407 applying 1,000 mg test substance/kg body weight/
day. Additionally, the acute phase proteins haptoglobin and 
α2-macroglobulin as well as cardiac troponin I were deter-
mined, and metabolome analysis was performed in plasma 
samples. There were no test substance-related adverse 
effects for any of the seven nanomaterials. Moreover, 
metabolomics changes were below the threshold of effects. 
Since test substance organ burden was not analyzed, it was 
not possible to establish whether the lack of findings related 
to the absence of systemic exposure of the tested nanomate-
rials or if the substances are devoid of any potential for tox-
icity. The few published subacute oral or short-term inhala-
tion studies investigating comparable nanomaterials (SiO2, 
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Upon ingestion, NMs can be taken up into the body. It 
is generally agreed that particle absorption in the gastroin-
testinal tract is low, but increases with decreasing particle 
diameter (Florence 2005; landsiedel et al. 2012b). Further, 
factors affecting oral NM uptake include particle surface 
charge, hydrophobicity, and the presence or absence of sur-
face ligands (Florence 1997). large inter-individual differ-
ences in NM uptake have been observed, and differences in 
the diet, in mucus secretion and composition, in pH values, 
in gastrointestinal transit time, and in gastrointestinal flora 
all have been recognized to influence NM uptake (Fröhlich 
and Roblegg 2012). In the intestine, the microfold cells 
(M cells) in the Peyer’s patches are important sites of NM 
uptake, but the enterocytes, the intestinal epithelial cells, 
also play an active role in particle translocation across 
the intestinal wall (Delie et al. 1998; Hillyer and Albrecht 
2001).
Oral uptake of nanoparticular food additives or ingre-
dients of cosmetic articles, etc., by consumers is likely to 
occur at low doses over long periods of time. Neverthe-
less, to date, only few reports on in vivo effects of NMs 
upon subacute or sub-chronic oral exposure to rodents are 
available (EFSA 2009; Dekkers et al. 2013). The majority 
of these investigations address the effects of silver nano-
particles, but different metal, metal oxide and carbon-based 
NMs were also evaluated, some of which causing histo-
pathological changes, e.g., in the liver or kidneys, or altera-
tions in blood parameters (Fröhlich and Roblegg 2012; van 
der Zande et al. 2012; Hadrup et al. 2012a; Dekkers et al. 
2013). The limited number of oral repeated-dose toxicity 
studies in rodents—and oftentimes the lack of standardi-
zation of substance characterization and testing methods, 
however, does not allow a final conclusion on the effects 
that different NMs might cause upon subacute or sub-
chronic oral administration.
Against this background, in the present study, the effects 
of a variety of different NMs upon 28-day oral exposure to 
rats were investigated. Due to their relevance for the oral 
route of exposure, different silicon dioxide (SiO2) and 
zirconium dioxide (ZrO2) NMs were selected for the oral 
toxicity studies, and they were compared to nanoparticu-
lar barium sulfate (BaSO4), for which extensive physico-
chemical information is already available since it is the 
OEcD reference nanomaterial NM-220 (OEcD 2008a; 
Hellack et al. 2012).
Amorphous SiO2 NMs are produced in annual volumes 
of megatons and have universal applications. As food addi-
tives, they are used, e.g., as anticaking agents (such as 
‘E551’) to prevent the clumping of powdered food prod-
ucts or to clarify liquids. Therefore, SiO2 NMs are espe-
cially relevant for oral uptake (Anon 2012; Wohlleben et al. 
2014). ZrO2 is a highly engineered nanomaterial, which 
is crystalline, instead of amorphous. It further has smaller 
particles than SiO2, with a size distribution [determined 
by transmission electron microscopy (TEM)] down to 
3 nm. Hence, testing SiO2 and ZrO2 NMs under the same 
experimental conditions allowed assessing possible size-
dependent NM effects. consumer-relevant applications of 
ZrO2 NMs are in self-cleaning coatings in stoves or other 
ceramic surfaces, and also in dental fillings or prostheses 
(Anon 2012; Hellack et al. 2012). Therefore, the oral route 
of exposure is also relevant for ZrO2 NMs.
Also the OEcD reference material BaSO4 NM-220 can 
be taken up orally: Micron-sized BaSO4 occurs can be 
ingested, and it is used as a radio-contrast agent, whereas 
the application of nanosized BaSO4 as an additive to dental 
cements or medicinal product materials is currently under 
investigation (Ricker et al. 2008; Aninwene et al. 2013).
To analyze the influence of physico-chemical character-
istics of NMs on their biological effects in vivo (Wohlleben 
et al. 2014), the SiO2 and ZrO2 NMs were selected having 
different, systematically varied surface functionalizations. 
In in vitro NM toxicology, NM charge and protein affinity 
(i.e., corona formation) are reported to affect the toxicity 
of otherwise identical substances. In order to test whether 
this hypothesis also holds true for in vivo toxicity, the func-
tionalizing agents were chosen to span the widest possible 
range of surface properties. Thereby, it was investigated 
how changes in NM structure affect their activity in bio-
logical systems, a necessary prerequisite to establishing 
structure–activity relationships (Wohlleben et al. 2014).
Based on these considerations, the following surface 
modifications were chosen: SiO2 NM was tested with 
negative (SiO2·phosphate), neutral [SiO2·polyethylene
glycol (SiO2·PEg)] and slightly positive (SiO2·amino) 
charges. ZrO2·TODS [with trioxadecanoic acid (TODS) 
surface modification] had the same slightly positive elec-
trical charge as SiO2·amino. With their short-chain func-
tionalizations, both of these substances were free of steric 
functionality. ZrO2·acrylate was strongly negative, thereby 
additionally introducing steric stabilization (oligomeric 
functionalization) that was found to effectively reduce 
corona formation (Wohlleben et al. 2014). The surface 
functionalization of the NMs and their delivery as dis-
persions, instead of powders, further served to prevent 
nanoparticle agglomeration optimizing their nanoform 
applicability in biological studies (Hellack et al. 2012). 
Additionally, SiO2 NM was tested without surface func-
tionalization, whereas ‘naked’ ZrO2·NMs that had already 
been assessed as being non-toxic in earlier in vitro and 
inhalation toxicity studies (Kuhlbusch et al. 2009) was not 
included in the present study.
The subacute oral toxicity studies were performed as 
limit tests in accordance with OEcD test guideline (Tg) 
407 (OEcD 2008b), since, from assessment of previous 
short-term inhalation studies (landsiedel et al. 2014), no 
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effects were expected at daily dosages of 1,000 mg/kg body 
weight. In addition to the basic hematological and clinical 
chemistry parameters listed in OEcD Tg 407, the acute 
phase proteins haptoglobin and α2-macroglobulin as well 
as cardiac troponin I were determined. Such biomarkers 
have been suggested as useful in detecting nanoparticle-
induced effects at very early stages preceding clinically 
observable effects (Higashisaka et al. 2011; Nagano et al. 
2012).
Additionally, metabolomics or ‘metabolite profiling’ 
based upon gas chromatography–mass spectrometry (gc–
MS) and liquid chromatography–mass spectrometry/mass 
spectrometry (lc–MS/MS) was performed in plasma sam-
ples (van Ravenzwaay et al. 2010a; Kamp et al. 2012a, b). 
Metabolomic investigations have been established as use-
ful tools to recognize early toxicological effects, already 
at stages preceding clinically observable findings. Metab-
olite level changes can be interpreted biochemically and 
by comparing alterations with those of about 500 refer-
ence compounds in the MetaMap®Tox database, thereby 
revealing possible toxicological modes of action (MoAs, 
i.e., the specific biochemical interactions through which a 
substance produces its influence on key processes in living 
organisms; van Ravenzwaay et al. 2007, 2010a, b, 2012a, 
b; EcETOc 2010; Kamp et al. 2010). Since changes are 
detectable in body fluids, such as urine and plasma, metab-
olomics have the potential to reduce and refine animal test-
ing. Furthermore, metabolomics might help bridging in 
vitro testing to in vivo relevance (EcETOc 2010), thereby 
possibly also contributing to replacing animal testing also 
for NM toxicity assessment.
In evaluating findings, special attention was paid to 
ensuring their consistent and transparent interpretation. To 
differentiate between adverse and non-adverse effects, the 
structured approach proposed by the European centre for 
Ecotoxicology and Toxicology of chemicals (EcETOc 
2002) was applied. To recognize adverse effects, the toxi-
cologist first has to apply defined criteria to decide whether 
differences from control values are treatment-related 
effects or occur by chance, i.e., incidentally. In a second 
step, again applying defined criteria, only those differences 
judged to be treatment-related are evaluated further to dis-
criminate between those that are adverse and those that are 
not (EcETOc 2002).
Materials and methods
Test substances and particle characterization
The following seven test substances were selected from 
the set of nanogEM test substances (Hellack et al. 2012; 
Wohlleben et al. 2014):
•	 SiO2·naked: SiO2 without surface modification (lev-
asil® 200);
•	 SiO2·PEg: levasil® 200 with covalent surface function-
alization with a low-molar-mass silane having a PEg 
end group with a molecular weight of 500 g/mol (PEg-
500), imparting some steric stabilization;
•	 SiO2·phosphate: levasil® 200 with covalent surface 
functionalization with a low-molar-mass silane having a 
negatively charged phosphonate end group on a flexible, 
short c3-linker;
•	 SiO2·amino: levasil® 200 with covalent surface func-
tionalization with a low-molar-mass silane having a pos-
itively charged amino end group on the same c3-linker;
•	 ZrO2·acrylate: ZrO2 with acrylate surface modification 
having a strongly negative electrical charge and impart-
ing steric stabilization;
•	 ZrO2·TODS: ZrO2 with trioxadecanoic acid (TODS) 
surface modification having a slightly positive electrical 
charge;
•	 BaSO4: reference material NM-220 from the OEcD 
Working Party for Manufactured Nanomaterials 
(WPMN) Sponsorship Programme for the Testing of 
Manufactured Nanomaterials (OEcD 2008a and 2010; cf. 
http://ihcp.jrc.ec.europa.eu/our_activities/nanotechnology/ 
nanomaterials-repository).
The SiO2 NMs were supplied by BASF SE, lud-
wigshafen, germany; the ZrO2 NMs by ceranovis Ag, 
Saarbrücken, germany; and BaSO4 NM-220 by Solvay, 
Brussels, Belgium. All test substances were delivered as 
dispersions, except for BaSO4, which was delivered as 
powder. All test substances were characterized in detail in 
accordance with the physico-chemical endpoints described 
in the guidance on information requirements for nanomate-
rials (EcHA 2012) to EU regulation No. 1907/2006 on the 
Registration, Evaluation, Authorisation and Restriction of 
chemicals (REAcH; Anon 2006). The following test sub-
stance properties were determined making use of the indi-
cated methodologies (Hellack et al. 2012; Wohlleben et al. 
2013; landsiedel et al. 2014):
Mean primary particle size and primary particle size 
(PPS) distribution (TEM); hydrodynamic particle size 
in water [dynamic light scattering (DlS) and analytical 
ultracentrifugation (AUc)]; particle morphology [light 
microscopy and scanning electron microscopy (SEM)]; 
crystallinity [x-ray diffraction (xRD)] surface chemistry, 
purity, and crystalline phase [x-ray photoelectron spectros-
copy (xPS)]; organic surface functionalization, [second-
ary ion mass spectrometry (SIMS)]; iso-electric point and 
zeta-potential (electrophoretic mobility titration); surface 
reactivity and radical formation potential (Electron spin 
resonance (ESR) making use of centrophenoxine (cPH) or 
dimethyl-pyrroline-N-oxide (DMPO) spin traps).
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For three sample substances, i.e., SiO2·naked, SiO2·PEg, 
and ZrO2·TODS, the state of agglomeration in the test 
substance vehicle of the 28-day oral toxicity studies, 
i.e., phosphate buffered saline (PBS) supplemented with 
1 g/l bovine serum albumin (BSA; in the following: 
‘PBS + BSA’), was determined by laser diffraction and 
AUc.
Due to limited test substance availability, the other 
nanomaterials could not be assessed in the vehicle of the 
present study. However, for all test substances, dispers-
ability in water or Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10 % fetal calf serum (FcS; 
in the following ‘DMEM + FcS’) were determined by 
AUc (Wohlleben et al. 2012, 2013; landsiedel et al. 2014). 
DMEM + FcS represents a biological medium that is com-
parable to the test substance vehicle. Therefore, NM dis-
persability is expected to be comparable in DMEM + FcS 
and PBS + BSA, and this data are included in Table 1 even 
though DMEM + FcS was not used as vehicle in the oral 
studies.
Preparation of test substances
The original test suspensions, as provided by the suppliers, 
were shaken and mixed for 2 min using a vortex mixer to 
ensure a homogeneous distribution of particles. Next, the 
desired amount of test substance was weighed and then 
filled up with the test substance vehicle PBS + BSA to 
obtain uniform test substance solutions of 10 wt% solu-
tions. Test substance preparations were produced daily and 
were kept homogenous until administration by continuous 
stirring with a magnetic stirrer.
Since NMs can agglomerate and sediment quickly in 
suspensions and this can considerably affect the final, 
effective dosage reaching the target organism, it is essential 
to assess the homogeneity of test substances and to verify 
the effective concentration in the test substance prepara-
tions. Therefore, at the onset of the administration period, 
homogeneity and concentration control analyses of all test 
substance suspensions (‘as delivered’ and ‘as prepared’ 
in PBS + BSA) were performed by inductively coupled 
plasma—optical emission spectrometry (IcP–OES). For 
this purpose, three separate samples of the test substance 
preparations were taken from the bottom, middle, and top 
layers of the vials (which would necessarily have the same 
test substance concentrations in homogenous suspensions).
The content of the metallic element of the respective test 
substances (i.e., silicon in the case of the SiO2 NMs, zirco-
nium in the case of the ZrO2 NMs, and barium for BaSO4) 
was measured and the mass of the entire test substance 
molecule derived from these measurements. The mass of 
the substances used for surface functionalization was con-
sidered to be negligible (RIP-oN 1 2011).
Study performance
The 28-day oral toxicity studies were performed with male 
and female Wistar crl:WI(Han) rats (charles River labo-
ratories, Sulzfeld, germany) following a five- or nine-day 
acclimatization period. The animals were 42 ± 1 days of 
age at the onset of the study and free from clinical signs. 
The animal facility that all animal work was performed in 
holds a certificate from the International Association for 
Assessment and Accreditation of laboratory Animal care 
(AAAlAc). The rats were housed in groups of 5 ani-
mals in polysulfonate cages (Tecniplast®, Hohenpeißen-
berg, germany; floor area approximately 2,065 cm2) with 
dust-free wooden bedding. Wooden gnawing blocks (Type 
NgM E-022; Abedd® lab. & Vet. Service gmbH, Vienna, 
Austria) were provided to the animals for environmen-
tal enrichment. The animal studies were performed with 
approval of the local regulatory agencies, and all study pro-
tocols complied with the federal guidelines.
The experiments were performed as limit tests in accord-
ance with OEcD Tg 407, applying uniform test substance 
dosages of 1,000 mg/kg body weight (bw)/day (cf. para-
graph 18 of OEcD Tg 407). The test substance preparations 
were administered daily by gavage over a period of 4 weeks 
to groups of 5 male and 5 female rats. For logistical reasons, 
the study had to be conducted in two separate sub-studies 
(albeit under otherwise identical experimental conditions), 
with SiO2·PEg, SiO2·phosphate, SiO2·amino, ZrO2·acrylate, 
and ZrO2·TODS tested in the first study (in the following 
‘sub-study A’) and SiO2·naked and BaSO4 NM-220 tested 
in the second study (‘sub-study B’). In each sub-study, con-
trol groups of 5 male and 5 female rats, each, received only 
the vehicle PBS + BSA. According to gad et al. (2006) and 
in-house experience, the test substance vehicle PBS is well 
tolerated by rats at dosages of 10 ml/kg body weight over 
administration periods of up to 1 month.
Details on the performance of the Detailed clinical 
Observations, regular health inspections, assessment of food 
and water consumption and the determination of the body 
weight are provided in the Supplementary Information (SI).
Hematological and clinical chemical examinations as well 
as urinalyses were performed toward the end of the admin-
istration period, and all standard parameters listed in OEcD 
Tg 407, paragraphs 32, 34, and 35, were evaluated for all 
animals. Additionally, the acute phase proteins haptoglobin 
and α2-macroglobulin were determined in serum samples 
from all animals and troponin I in serum samples from the 
animals used in sub-study A. Further details on the blood 
sampling and assessment of hematological parameters, clini-
cal chemistry, and urinalysis are provided in the SI.
In evaluating the blood parameter results from the test 
groups, the data were compared not only to the corre-
sponding data recorded for the control groups, but also to 
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historical control data from unpublished in-house studies 
(except for the parameter ‘acute phase proteins’ for female 
rats, for which no historical control data were available; cf. 
SI for details on the unpublished in-house data).
Upon completion of the administration period, all rats 
were killed by decapitation under isoflurane anesthesia after 
food withdrawal for at least 16 h (except for the one female 
animal of the SiO2·naked test group that died due to gav-
age error). The exsanguinated animals were subjected to 
a full, detailed gross necropsy assessing and weighing all 
organs listed in OEcD Tg 407, paragraph 40. Additionally, 
all organs listed in OEcD Tg 407, paragraph 43, were pre-
served in neutral-buffered 10 % formalin (NBF) or modified 
Davidson’s solution for histopathological examination. After 
paraplast embedding, the paraplast blocks were cut with 
2–3-µm thickness, cuts were mounted on glass slides and 
stained with hematoxylin and eosin (H&E; Merck, Darm-
stadt, germany) for light microscopic assessment. As appro-
priate, any findings were either marked as being ‘present’ 
or they were graded (1–5) with increasing severity (minimal 
to massive), increasing numbers of affected units, etc. (very 
few to extensive numbers), or increasing size of affected tis-
sue, etc. (very small to extensive size). All histopathological 
assessments were performed by a well-experienced board-
certified (DEcVP) veterinarian toxicopathologist.
Metabolome analysis with MetaMap®Tox methodology
As described by van Ravenzwaay et al. (2007) and Kamp 
et al. (2012a), EDTA-K3 blood samples of all rats taken 
on study day 28 were analyzed in regard to their metabo-
lite profiles upon metabolite extraction by a proprietary 
method: gc–MS and lc–MS/MS were applied for broad 
profiling and hormone measurement. The method resulted 
in 225 semi-quantitative analytes, 171 of which are chemi-
cally identified and 54 are structurally unknown. Analysis 
of the recorded metabolite profiles was performed making 
use of the MetaMap®Tox database (van Ravenzwaay et al. 
2012a; cf. Information box MetaMap®Tox methodology).
Information box: MetaMap®Tox methodology
The MetaMap®Tox database encompasses the metabolome profiles 
from rat plasma for approximately 500 pharmaceuticals, chemicals, 
and agrochemicals. These data had been determined by a special 
28-day study protocol including control groups and low- and high-
dose test groups of 5 male and 5 female crl:WI(Han) rats, each, and 
plasma sampling after 7-, 14-, and 28-day test substance exposure. 
Discriminating metabolite patterns for various toxicological MoAs 
have been developed based on the common metabolome changes 
induced by (as a rule) at least three different chemicals included 
in the MetaMap®Tox database that share a common toxicological 
MoA (i.e., the reference compounds). Iteratively, an expert panel of 
experienced toxicologists modifies the list of metabolites in order to 
obtain sufficient sensitivity and selectivity against the reference data 
in the database.
During the evaluation of blood samples, the pattern ranking itself is a 
two-step process. First, applying a median r value metric, an algorithm 
used in the database yields a ranking list that is based on similarity 
of the metabolic profile of the test compound in comparison with the 
specific patterns listed in MetaMap®Tox. Second, the expert panel of 
experienced toxicologists evaluates the metabolite changes to deter-
mine which pattern matches might constitute ‘confirmed’ matches. 
In the course of this evaluation, the number of consistently changed 
metabolites as well as quality and importance of the metabolite 
changes for a given toxicological MoA is taken into consideration.
The European centre for Ecotoxicology and Toxicology of chemicals 
has defined criteria to determine adverse effects based on ‘-omics’ 
data (EcETOc 2008, 2010, 2013). According to these criteria, an 
adverse effect has to be based on, firstly, a significant overall effect 
within the data set and, secondly, the presence of changes that can 
be attributed to an adverse and clinically relevant phenotypical effect, 
either on the basis of biological pathway information or by com-
parison with reference data, which are predictive for the respective 
adverse effects. In fulfilling these prerequisites, the contents of the 
data base MetaMap®Tox, and particularly the specific toxicity pat-
terns, can serve to define an adverse effect based on metabolome data.
Statistical analysis and interpretation of findings
All quantifiable test results were calculated as means and 
standard deviations of each test group. Additionally, the 
following statistical analyses were performed:
•	 Body weight and body weight change: A comparison of 
each group with the control group using Dunnett’s test 
(two sided) for the hypothesis of equal means;
•	 Blood and urine parameters with uni- or bidirec-
tional changes: One or two-sided Wilcoxon test for the 
hypothesis of equal medians;
•	 Blood and urine parameters with unidirectional changes: 
Pair-wise, one-sided Wilcoxon test for the hypothesis of 
equal medians;
•	 Organ weight parameters: A pair-wise comparison of each 
dose group with the control group was performed using 
the Wilcoxon test for the hypothesis of equal medians.
In all tests, levels of significance of p ≤ 0.05 (*) and 
p ≤ 0.01 (**) were recorded.
To relate statistical findings to true adverse biological 
effects, the following criteria were applied as specified by 
EcETOc (2002):
•	 Establish that there is a difference between the test 
groups and control groups.
•	 Is the difference an effect of the treatment or is it inci-
dental (i.e., has it arisen by chance)?—A difference is 
less likely to be treatment-related if, e.g., it is caused by 
findings in one or more animals, which could be consid-
ered outliers, if it is within the range of historical con-
trol values, or if it lacks biological plausibility (i.e., it is 
inconsistent with known MoAs).
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•	 Is the treatment-related effect adverse?—Findings are 
less likely to be adverse if, e.g., the general function of 
the test organism or of the affected organ remains unaf-
fected or findings occur in isolation (i.e., changes in 
other parameters usually associated with the effect of 
concern are not observed).
Results
Test substance characterization
An overview of the primary and secondary physico-chemi-
cal properties of the test substances is provided in Table 1, 
which has been adapted from Wohlleben et al. (2013) and 
landsiedel et al. (2014). Further information on the prepa-
ration and characterization of the set of nanogEM test sub-
stances is available from Hellack et al. (2012).
As recorded in Table 1, all test substances were well dis-
persed in water and had average agglomeration numbers 
(AAN, i.e., the average number of primary particles in the 
agglomerate) of 1 (or 3, in the case of ZrO2·acrylate). Only 
BaSO4 NM-220, which was not provided as suspension, 
but as powder, had a higher AAN of 11. In PBS + BSA, 
SiO2·PEg and ZrO2·TODS prevailed as large agglomer-
ates above 1 μm, and the BSA concentration in these solu-
tion was significantly reduced, indicating BSA adsorption 
onto the test materials. SiO2·naked, however, remained 
stable in PBS + BSA with only minimal agglomera-
tion, but also here BSA adsorption was recorded. When 
diluted in DMEM + FcS, only SiO2·phosphate remained 
well dispersed (AAN of 1 or 2), whereas all other NMs 
were moderately (AAN = 28 and 32 for SiO2·naked and 
ZrO2·acrylate, respectively) or strongly agglomerated 
(AAN = 86, 90, and 213 for ZrO2·TODS, SiO2·amino and 
SiO2·PEg, respectively).
The iso-electric points of the test substances ranged 
from pH values above 7 for SiO2·amino and ZrO2·TODS 
to between 3 and 4.5 for SiO2·PEg and BaSO4 NM-220 to 
below 1 for SiO2·naked, SiO2·phosphate, and ZrO2·acrylate.
concentration and homogeneity control analysis
Sub-study A: Ranging between 9.6 and 10.3 g test substance 
per 100 g preparation, the results of the concentration con-
trol analysis confirmed the correctness of the concentra-
tions of the surface-functionalized SiO2 and ZrO2 NMs in 
the PBS + BSA preparations. likewise, the overall identi-
cal concentrations determined in the bottom, middle, and top 
layers of the suspensions confirmed that the substances were 
distributed homogeneously in the vehicles (Table 2).
Sub-study B: As revealed by differing concentrations 
measured in the three samples, SiO2·naked was not dis-
tributed homogeneously in the test substance preparations. 
The mean of all 3 samples, however, confirmed the over-
all 10 wt% suspension, most likely an indication that the 
remaining particles had sedimented to the bottom of the 
vials. Also BaSO4 was not distributed homogeneously in 
the test substance preparations, and only contained an aver-
age of 6.5 g BaSO4 per 100 g (Table 2).
Findings recorded in the 28-day oral toxicity study
Food and water consumption, clinical examination, body 
weight gain
In sub-studies A and B, food and water consumption of all 
test animals was unaffected by all applied test substances.
Table 2  concentration control analysis of test substance suspensions (‘as delivered’ and ‘as prepared’)
In the vials, samples 1–3 are taken from the bottom, middle, and top layers of the suspensions
The mass of the test substances only corresponds to the mass of the core nanomaterial, and not to the molecules of the surface functionalization 
material that was only present in the preparations in negligible concentrations (Hellack et al. 2012)
Sub-study Test substance concentration control analysis












Mean of samples 
1–3 (g/100 g)
A SiO2·PEg 20 20.1 10.1 10.1 10.1 10.1
A SiO2·phosphate 20 20.4 10.3 10.3 10.3 10.3
A SiO2·amino 20 20.1 10.3 10.3 10.3 10.3
A ZrO2·acrylate 35 33.8 9.6 9.6 9.6 9.6
A ZrO2·TODS 45 43.3 9.9 9.9 10.1 10.0
B SiO2·naked 40 39.2 7.9 7.9 11.6 9.1
B BaSO4 NM-220 Powder 92.7 6.6 7.3 5.4 6.5
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Sub-study A: Upon clinical examination, no test sub-
stance-related adverse effects were observed in any of 
the test groups. In the males of the SiO2·PEg test group, 
on study day 28, body weight change values were signifi-
cantly increased by 20 % as compared to the control group 
(Table 3). Since this finding did not correspond to any other 
observable effect, it was considered to be incidental and not 
treatment-related in accordance with the EcETOc (2002) 
criteria.
Sub-study B: One female animal of the SiO2·naked test 
group was found dead on study day 5. The animal died 
because of a gavage error. In none of the male or female 
animals of sub-study B, significant changes in regard to 
mean body weights were observed (Table 3).
clinical pathology
Hematology
For none of the test groups, recorded changes in hemato-
logical parameters were assessed as being related to the 
treatment with the respective nanomaterials.
Sub-study A (Tables 4, 5): In the male animals of the 
SiO2·PEg test group, the mean relative reticulocyte (Ret. 
%) and platelet counts (PlT) were higher than those 
of the control group (i.e., 2.6 % as compared to 2.1 %; 
and 975 giga/l as compared to 851 giga/l), and in the 
female animals of this test group, the Ret. % counts were 
decreased (i.e., 2.1 % as compared to 2.5 %). In the males 
of the SiO2·phosphate test group, the PlT counts were 
elevated (935 vs. 851 giga/l), and in the females of this 
test group, the hemoglobin (HgB) values were decreased 
(8.2 mmol/l; control animals: 8.5 mmol/l). Since all of 
these values were within the respective historical control 
ranges (Tables 4, 5; cf. Supplementary Information for 
details on the historical control data collected in in-house 
studies), all alterations were assessed as incidental and not 
treatment-related in accordance with the EcETOc (2002) 
criteria. No white blood cell parameters were changed in 
either the male or the female rats of any test group of sub-
study A.
Sub-study B (Tables 4, 5): No red blood cell or coagu-
lation parameters were changed in the male rats of sub-
study B. Regarding white blood cell parameters, in the 
male animals of the SiO2·naked test group, relative eosin-
ophil (Eos.%) counts were lower as compared to the con-
trol group (1.0 vs. 1.5 %; Tables 5). The recorded value, 
however, was only marginally below the historical control 
range (1.1–2.8 %), the absolute eosinophil counts were not 
altered (data not shown), and none of the other differential 
blood cell fractions were changed. Furthermore, the eosin-
ophil counts were not changed in the female animals of the 
same test group. Therefore, these alterations were regarded 
as incidental and not treatment-related in accordance with 
the EcETOc (2002) criteria.
In the female animals of the BaSO4 test group, the HgB 
and hematocrit (HcT) values (8.7 mmol/l and 0.415 l/l) 
as well as the absolute and relative large unstained cell 
Table 3  Body weight; all test substances applied daily at 1,000 mg/kg body weight for 28 days; body weight (g), expressed as mean of test 
group (N = 5, except otherwise indicated)
* Significant (p ≤ 0.5) body weight change relative to the control group by more than 20 %


















0 160 161 162 159 162 162 128 128 127 127 129 127
7 202 206 206 203 205 205 141 149 144 147 148 145
14 238 249 249 246 247 247 159 170 165 164 168 163
21 268 286 279 282 285 275 176 184 178 183 185 176
28 282 307* 302 300 306 292 182 192 183 190 192 186
Day Male animals Female animals
control group SiO2·naked BaSO4 control group SiO2·naked (N = 4) BaSO4
Sub-study B
0 164 167 169 132 130 134
7 204 211 211 149 151 153
14 239 248 252 168 166 174
21 265 275 280 180 178 191
28 286 295 301 192 183 200
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Table 4  Hematology: Red blood cell and coagulation parameters (determined on day 29), expressed as mean of test group (N = 5; except other-
wise indicated)
RBC red blood cells, HGB hemoglobin, HCT hematocrit, MCV mean corpuscular volume, MCH mean corpuscular hemoglobin, MCHC mean 
corpuscular hemoglobin concentration, RET reticulocytes, PLT platelets, HQT prothrombin time (Heptatoquick® test)
Units giga/l = 109/liter; tera/l = 1012/liter; fl = fentoliter; mmol/l = millimole/liter; fmol = fentomole; l/l = liter/liter; sec = seconds
Significance, as compared to the control group: * p ≤ 0.5 ; ** p ≤ 0.1
a
 Historical control range (N = 37 for male and female rats, respectively): unpublished in-house data, see Supplementary Information for details
b
 Female animals of test group SiO2·naked: N = 4
Historical control rangea control group SiO2·PEg SiO2·phosphate SiO2·amino ZrO2·acrylate ZrO2·TODS
Sub-study A
Male animals
 RBc; tera/l 7.59–8.60 8.28 8.16 8.27 8.27 8.14 8.10
 HgB; mmol/l 8.6–9.5 8.9 8.9 8.9 8.9 8.8 8.9
 HcT; l/l 0.384–0.432 0.427 0.428 0.431 0.432 0.429 0.424
 McV; fl 48.1–53.3 51.6 52.5 52.0 52.3 52.7 52.3
 McH; fmol 1.06–1.19 1.07 1.08 1.08 1.07 1.08 1.09
 McHc; mmol/l 20.43–23.73 20.75 20.68 20.70 20.57 20.57 20.90
 RET; % 1.4–3.1 2.1 2.6* 2.4 2.3 2.3 2.4
 PlT; giga/l 791–1,025 851 975** 935* 807 883 909
 HQT; sec 33.3–39.6 38.1 37.5 38.7 38.7 38.2 38.2
Female animals
 RBc; tera/l 7.15–8.12 7.46 7.48 7.47 7.67 7.41 7.34
 HgB; mmol/l 8.1–9.1 8.5 8.4 8.2* 8.6 8.4 8.3
 HcT; l/l 0.358–0.405 0.403 0.402 0.390 0.404 0.396 0.395
 McV; fl 48.5–53.2 54.1 53.7 52.4 52.8 53.5 53.9
 McH; fmol 1.09–1.22 1.14 1.13 1.10 1.12 1.13 1.13
 McHc; mmol/l 20.99–24.34 20.97 20.95 20.96 21.20 21.21 21.03
 RET; % 1.6–4.6 2.5 2.1* 2.3 2.1 2.2 2.5
 PlT; giga/l 779–1,022 952 927 877 675 884 877
 HQT; sec 30.3–36.7 35.3 35.5 35.6 34.8 34.9 35.8
Historical control rangea control group SiO2·nakedb BaSO4
Sub-study B
Male animals
 RBc; tera/l 7.59–8.60 7.94 8.27 8.14
 HgB; mmol/l 8.6–9.5 8.9 8.8 9.1
 HcT; l/l 0.384–0.432 0.432 0.425 0.440
 McV; fl 48.1–53.3 54.5 51.4 54.1
 McH; fmol 1.06–1.19 1.12 1.07 1.11
 McHc; mmol/l 20.43–23.73 20.58 20.81 20.59
 RET; % 1.4–3.1 2.2 2.1 2.2
 PlT; giga/l 791–1,025 836 792 844
 HQT; sec 33.3–39.6 37.1 33.9 38.4
Female animals
 RBc; tera/l 7.15–8.12 7.32 7.89 7.89
 HgB; mmol/l 8.1–9.1 8.2 8.7 8.7**
 HcT; l/l 0.358–0.405 0.392 0.414 0.415**
 McV; fl 48.5–53.2 53.6 52.4 52.7
 McH; fmol 1.09–1.22 1.13 1.10 1.11
 McHc; mmol/l 20.99–24.34 21.07 21.10 21.03
 RET; % 1.6–4.6 2.4 2.0 2.1
 PlT; giga/l 779–1,022 745 796 823
 HQT; sec 30.3–36.7 34.2 33.8 34.5
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Table 5  Hematology: White blood cell parameters (determined on day 29), expressed as mean of test group (N = 5; except otherwise indicated)
WBC white blood cells, LUC large unstained cells, Neut. polymorphonuclear neutrophils, Lymph. lymphocytes, Mono. monocytes, Eos. eosino-
phils, Baso. basophils
Units: giga/l = 109/liter
Significance, as compared to the control group: * p ≤ 0.5
a
 Historical control range (N = 37 for male and female rats, respectively): unpublished in-house data, see Supplementary Information for details
b
 Female animals of test group SiO2·naked: N = 4
Historical control rangea control group SiO2·PEg SiO2·phosphate SiO2·amino ZrO2·acrylate ZrO2·TODS
Sub-study A
Male animals
 WBc; giga/l 4.38–7.90 4.94 4.22 6.20 4.86 4.57 5.52
 lUc; giga/l 0.01–0.05 0.02 0.02 0.03 0.02 0.02 0.02
 lUc; % 0.3–0.8 0.4 0.4 0.4 0.4 0.5 0.3
 Neut.; % 9.4–16.6 12.5 11.3 14.0 10.3 10.6 11.5
 lymph.; % 79.1–87.0 84.5 85.2 82.5 86.5 85.8 84.9
 Mono.; % 0.9–2.5 1.2 1.4 1.6 1.5 1.4 1.5
 Eos.; % 1.1–2.8 1.1 1.3 1.1 1.0 1.2 1.3
 Baso.; % 0.0–0.9 0.3 0.3 0.3 0.3 0.5 0.4
Female animals
 WBc; giga/l 3.06–5.08 2.84 3.17 3.12 3.28 3.26 3.14
 lUc; giga/l 0.01–0.03 0.01 0.01 0.01 0.02 0.01 0.01
 lUc; % 0.2–0.7 0.3 0.5 0.4 0.5 0.3 0.4
 Neut.; % 7.9–19.5 11.4 8.4 11.3 9.3 9.7 11.8
 lymph.; % 76.3–88.2 85.0 88.4 85.4 87.1 86.8 84.4
 Mono.; % 1.0–2.3 1.3 1.0 1.4 1.3 1.1 1.1
 Eos.; % 1.0–3.0 1.6 1.4 1.2 1.5 1.6 2.0
 Baso.; % 0.0–0.8 0.4 0.3 0.3 0.4 0.4 0.3
Historical control rangea control group SiO2·nakedb BaSO4
Sub-study B
Male animals
 WBc; giga/l 4.38–7.90 6.30 5.86 5.49
 lUc; giga/l 0.01–0.05 0.04 0.05 0.03
 lUc; % 0.3–0.8 0.6 1.0 0.5
 Neut.; % 9.4–16.6 12.8 16.6 12.3
 lymph.; % 79.1–87.0 83.0 78.7 83.8
 Mono.; % 0.9–2.5 1.7 2.4 1.7
 Eos.; % 1.1–2.8 1.5 1.0* 1.1
 Baso.; % 0.0–0.9 0.4 0.3 0.5
Female animals
 WBc; giga/l 3.06–5.08 3.97 4.99 4.95
 lUc; giga/l 0.01–0.03 0.02 0.04 0.04*
 lUc; % 0.2–0.7 0.5 0.8 0.8*
 Neut.; % 7.9–19.5 19.1 24.1 10.5
 lymph.; % 76.3–88.2 77.5 71.1 84.7
 Mono.; % 1.0–2.3 1.2 2.0 1.5
 Eos.; % 1.0–3.0 1.3 1.8 2.1
 Baso.; % 0.0–0.8 0.4 0.3 0.5
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(lUc) counts (0.04 giga/l and 0.8 %) were higher than 
those recorded for the related control group (HgB: 
8.2 mmol/l; HcT: 0.392 l/l; absolute and relative lUc: 
0.02 giga/l and 0.5 %; Tables 4, 5). Whereas the HgB and 
HcT values were within historical control ranges (8.1–
9.1 mmol/l and 0.358–0.405 l/l, respectively), the lUc 
counts were slightly higher than the historical control val-
ues (absolute and relative lUc: 0.01–0.03 giga/l and 0.2–
0.7 %). Since the lUc were the only fraction of the differ-
ential blood cell count that was altered and the lUc counts 
in the male rats of the BaSO4 test group were unchanged, 
all of these hematological alterations were also assessed as 
incidental and not treatment-related in accordance with the 
EcETOc (2002) criteria.
Clinical chemistry and acute phase proteins
For none of the test groups, recorded changes in clini-
cal chemistry parameters or the acute phase proteins were 
assessed as being adverse and related to the NM treatment.
Sub-study A (Table 6): In the male animals of the 
SiO2·PEg and ZrO2·TODS test groups, the chloride levels 
were lower than those recorded for the control group (102.7 
and 102.9 mmol/l, vs 104.9 mmol/l). In the female ani-
mals of the ZrO2·acrylate test group, alanine aminotrans-
ferase (AlT) activities were increased (0.68 µkat/l as 
compared to 0.53 µkat/l), and in the female animals of the 
SiO2·phosphate test group, total protein, albumin, and glob-
ulin levels were decreased (59.27, 39.68, and 19.59 g/l, 
respectively, as compared to 64.91, 43.02, and 21.90 g/l). 
Apart from the globulin levels recorded for the female 
animals of the SiO2·phosphate group, all of these find-
ings were within the respective historical control ranges 
(male rats: chloride: 99.2–104.0 mmol/l; female rats: 
AlT: 0.46–0.80 µkat/l; total protein: 58.40–66.16 g/l; 
albumin: 35.44–40.66 g/l; globulin: 21.07–26.27 g/l; 
Table 6 and Supplementary Information). Therefore, they 
were regarded as incidental and not treatment-related. 
Since the globulin levels were in fact marginally below the 
historical control range, this alteration was regarded as pos-
sibly treatment-related, but not adverse (EcETOc 2002).
In none of the test groups of sub-study A, significant 
changes in the haptoglobin, α2-macroglobin, or troponin I 
levels were recorded. For cardiac troponin I, all values were 
furthermore below the sensitivity level of the assay. There-
fore, this parameter was excluded from the evaluation in 
sub-study B (and the parameter is not recorded in Table 6).
Sub-study B (Table 6): In the male animals of the 
SiO2·naked and BaSO4 test groups, haptoglobin values 
were higher than those recorded for the control group 
(413.6 and 374.3 ng/ml, respectively, as compared to 
234.0 ng/ml). However, these haptoglobin values were 
within the historical control range (haptoglobin: 265.2–
1.074.0 ng/ml, corresponding to a range of fourfold 
between the lowest and the highest mean of control groups 
previously recorded in unpublished in-house studies; cf. 
Supplementary Information). Of note, the mean hapto-
globin value recorded for the control group of sub-study 
A (1,523.0 ng/ml) exceeded this historical control range 
value, whereas the mean haptoglobin value recorded for the 
control group of sub-study B (234.0 ng/ml) was slightly 
below it. In regard to the present survey, these observa-
tions were assessed as incidental in accordance with the 
EcETOc (2002) criteria, and they might be an indication 
that the historical control range should be considered as 
preliminary.
In the female rats of the SiO2·naked test group, the mean 
haptoglobin values were also considerably higher than 
those recorded for the respective control group (469.5 ng/
ml as compared to 141.7 ng/ml). Assessment of the impli-
cations of these values is impaired by the circumstance that 
historical control ranges for haptoglobin values in female 
rats were neither available in-house, nor could be found in 
the published literature. Additionally, one of these animals 
not only had an extremely high haptoglobin value (i.e., 
1,610.2 ng/ml; data for individual animals not shown), 
but also a high α2-macroglobulin value (49.21 ng/ml as 
compared to the mean control value of 12.65 ng/ml) and 
increased total white blood cell (WBc) and (absolute and 
relative) neutrophil counts [WBc: 8.44 as compared to 
3.97 giga/l; neutrophils: 5.36 giga/l (63.5 %) as compared 
to 0.66 giga/l (19.1 %)]. Upon necropsy, no macroscopic 
or histopathological correlates to these findings could be 
determined. Therefore, this individual animal was diag-
nosed as most likely having had a systemic inflammation. In 
addition, for the other three (remaining) animals of this test 
group (one animal of this test group had died due to gav-
age error), all mentioned parameters were within the nor-
mal ranges, and there were no histopathologically relevant 
findings upon necropsy. (When excluding the haptoglobin 
value of 1,610.2 ng/ml, the mean haptoglobin value of the 
remaining animals of the SiO2·naked test group amounted 
to 89.3 ng/ml, i.e., it was even lower than the mean con-
trol value). Therefore, the mean haptoglobin value of the 
female rats of the SiO2·naked test group, just as the altered 
parameters of the individual female rat, was assessed as not 
being related to the test substance SiO2·naked in accord-
ance with the EcETOc (2002) criteria.
Urinalysis
Neither in sub-studies A nor B, any treatment-related, 
adverse changes of any of the urine parameters assessed 
were recorded.
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Table 6  clinical chemistry (i.e., enzymes, electrolytes and minerals, substrates, acute phase proteins; determined on day 29), expressed as mean 
of test group (N = 5; except otherwise indicated)
Historical control rangea control group SiO2·PEg SiO2·phosphate SiO2·amino ZrO2·acrylate ZrO2·TODS
Sub-study A
Male animals
 AlT; µkat/l 0.53–0.89 0.62 0.63 0.65 0.65 0.63 0.73
 AST; µkat/l 1.46–2.42 1.82 1.70 1.89 1.81 1.66 1.85
 AP; µkat/l 1.50–2.80 2.79 2.37 2.72 2.46 2.58 2.17
 ggT; nkat/l 0–13 0 0 0 0 0 0
 TP; g/l 59.09–65.07 62.25 61.53 62.63 60.85 62.10 61.74
 Alb; g/l 35.28–38.41 40.27 39.57 40.14 39.63 40.09 39.73
 glob; g/l 22.15–28.70 21.98 21.96 22.50 21.22 22.01 22.01
 Na; mmol/l 139.1–146.0 146.4 145.2 145.7 145.1 146.1 144.6
 K; mmol/l 4.29–4.91 4.38 4.61 4.37 4.56 4.41 4.52
 cl; mmol/l 99.2–104.0 104.9 102.7* 103.2 103.6 103.2 102.9*
 INP; mmol/l 1.88–2.39 1.98 2.05 2.07 1.99 1.94 2.04
 ca; mmol/l 2.42–2.70 2.52 2.51 2.53 2.46 2.50 2.49
 Urea, mmol/l 4.69–7.67 5.90 5.54 5.81 5.49 5.43 5.51
 crea; µmol/l 43.9–52.5 49.0 47.3 49.0 47.5 48.1 50.1
 TBIl; µmol/l 1.46–2.63 2.29 2.96 2.66 2.23 2.75 2.52
 Hapt; ng/ml 265.2–1,074.0 1,523.0 853.0 1,399.8 1,383.80 1,837.6 1,724.0
 α2 m; ng/ml 8.92–33.77 15.68 14.91 15.17 14.79 13.86 15.59
Female animals
 AlT; µkat/l 0.46–0.80 0.53 0.53 0.51 0.69 0.68* 0.67
 AST; µkat/l 1.36–2.69 1.85 1.70 1.88 2.34 2.21 2.09
 AP; µkat/l 0.71–2.01 1.56 1.56 1.65 1.46 1.59 1.62
 ggT; nkat/l 0–17 1 0 1 0 0 0
 TP; g/l 58.40–66.16 64.91 63.87 59.27** 62.06 62.76 62.61
 Alb; g/l 35.44–40.66 43.02 42.60 39.68** 41.26 41.53 41.91
 glob; g/l 21.07–26.27 21.90 21.27 19.59* 20.80 21.22 20.70
 Na; mmol/l 138.9–144.3 145.9 146.0 144.9 145.3 146.2 146.5
 K; mmol/l 3.79–4.41 4.11 4.16 4.03 4.16 3.98 4.16
 cl; mmol/l 100.1–104.8 106.0 105.9 106.0 105.1 105.9 106.5
 INP; mmol/l 1.52–2.01 1.78 1.84 1.89 1.82 1.69 1.80
 ca; mmol/l 2.43–2.65 2.50 2.55 2.45 2.53 2.59 2.49
 Urea, mmol/l 5.74–8.49 5.65 5.89 5.67 5.58 6.07 5.55
 crea; µmol/l 47.0–56.1 49.2 47.7 51.3 48.7 51.6 49.1
 TBIl; µmol/l 1.51–2.88 1.26 0.96 0.83 1.43 1.21 1.39
 Hapt; ng/ml Not available 695.0 403.6 585.8 453.0 698.2 689.0
 α2 m; ng/ml Not available 16.93 15.78 12.46 17.84 14.72 16.32
Historical control rangea control group SiO2·nakedb BaSO4
Sub-study B
Male animals
 AlT; µkat/l 0.53–0.89 0.80 0.76 0.80
 AST; µkat/l 1.46–2.42 1.99 2.10 2.26
 AP; µkat/l 1.50–2.80 2.35 1.99 2.39
 ggT; nkat/l 0–13 0 0 0
 TP; g/l 59.09–65.07 60.20 62.34 62.76
 Alb; g/l 35.28–38.41 37.53 38.20 39.02
 glob; g/l 22.15–28.70 22.67 24.13 23.74
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Pathology
Absolute and relative organ weights
Sub-study A: When compared to the respective control 
groups (whose organ weights were set as 100 %), the abso-
lute weight of the epididymides was significantly decreased 
in the male rats of the SiO2·PEg test group, and the absolute 
weights of the heart and spleen were increased in the male 
rats of the SiO2·amino test group (Table 7). Also in regard to 
relative organ weight, the weight of the epididymides of the 
SiO2·PEg test group was decreased. Furthermore, the rela-
tive weights of the prostate and testes of the male animals of 
the ZrO2·acrylate test group were decreased (Table 8).
For the female rats, the mean absolute weight of the 
uterus was decreased in the SiO2·phosphate test group 
(assessed as being cycle-related), and the relative weights 
of the kidneys and thymus were decreased in the animals of 
the SiO2·amino and Zr·O2·acrylate (only kidney) test groups 
(Tables 7, 8).
All of these changes were assessed as not being treat-
ment-related in accordance with the EcETOc (2002) 
ALT alanine aminotransferase, AST aspartate aminotransferase, AP alkaline phosphatase, gGT gamma glutamyl transferase; TP total protein, Alb. 
albumin, Glob. globulins, Na sodium, K potassium, Cl chloride, INP inorganic phosphate, Ca calcium, Crea. creatinine, TBIL total bilirubin, 
Hapt. haptoglobin, α2m α2-macroglobin
Significance, as compared to the control group: * p ≤ 0.5 ; ** p ≤ 0.1
Units: µkat/l = microkatal per liter; nkat/l = nanokatal per liter; ng/ml = nanogram per milliliter; g/l = gram per liter; mmol/l = millimole 
per liter
a
 Historical control range (N = 37 for male and female rats, respectively, except for acute phase proteins: N = 23 for male rats, and no historical 
controls available for female rats): unpublished in-house data, see Supplementary Information for details
b
 Female animals of test group SiO2·naked: N = 4
Table 6  continued
Historical control rangea control group SiO2·nakedb BaSO4
 Na; mmol/l 139.1–146.0 141.8 140.5 141.8
 K; mmol/l 4.29–4.91 4.45 4.52 4.59
 cl; mmol/l 99.2–104.0 101.7 100.4 100.9
 INP; mmol/l 1.88–2.39 2.15 2.01 2.15
 ca; mmol/l 2.42–2.70 2.53 2.53 2.54
 Urea, mmol/l 4.69–7.67 5.77 6.23 5.54
 crea; µmol/l 43.9–52.5 45.1 47.5 46.5
 TBIl; µmol/l 1.46–2.63 1.40 1.38 1.28
 Hapt.; ng/ml 265.2–1,074.0 234.0 413.6* 374.3*
 α2 m; ng/ml 8.92–33.77 11.08 14.29 11.25
Female animals
 AlT; µkat/l 0.46–0.80 0.59 0.54 0.52
 AST; µkat/l 1.36–2.69 1.95 1.87 1.71
 AP; µkat/l 0.71–2.01 1.19 0.91 0.93
 ggT; nkat/l 0–17 0 0 0
 TP; g/l 58.40–66.16 61.05 61.07 62.08
 Alb; g/l 35.44–40.66 39.44 39.17 40.23
 glob; g/l 21.07–26.27 21.61 21.90 21.85
 Na; mmol/l 138.9–144.3 140.0 139.0 139.9
 K; mmol/l 3.79–4.41 4.01 3.92 4.09
 cl; mmol/l 100.1–104.8 101.9 99.6 100.8
 INP; mmol/l 1.52–2.01 1.68 1.68 1.83
 ca; mmol/l 2.43–2.65 2.50 2.52 2.56
 Urea, mmol/l 5.74–8.49 6.06 5.66 6.35
 crea; µmol/l 47.0–56.1 51.6 50.7 49.2
 TBIl; µmol/l 1.51–2.88 1.08 0.97 1.60
 Hapt.; ng/ml Not available 141.7 469.5 153.3
 α2 m; ng/ml Not available 12.65 20.80 13.89
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criteria since they did not correspond to any histopathologi-
cal findings and since (apart from the reduced weight of 
the epididymides of the SiO2·PEg test group) absolute and 
relative changes in organ weight did not correlate.
Sub-study B: There were no significant increases or 
decreases of the mean absolute organ weights in any of the 
test groups as compared to the respective control group val-
ues. In regard to mean relative organ weights, the weight of 
the liver of the male animals of the SiO2·naked test group 
was increased and the hearts of the female animals of the 
BaSO4 test group were decreased (Table 8). Again, all of 
these changes were assessed as not being treatment-related 
in accordance with the EcETOc (2002) criteria since there 
were no corresponding changes in absolute organ weights 
or histopathological findings that would explain the weight 
changes.
Table 7  Pathology (absolute weights, expressed as mean of test group (N = 5) relative to respective control group)
For sub-study B, there are no significant increases or decreases of the mean absolute organ weights in any of the test groups as compared to the 
respective control group values
For all other organs (i.e., adrenal glands, brain, kidneys, liver, ovaries (female), prostate (male), seminal vesicle (male), testes (male), thymus, 
thyroid glands) and the terminal body weight, no significant changes in absolute weights, relative to the control group, are determined
Significance, as compared to the control group: * p ≤ 0.5
Affected organ control group (%) SiO2·PEg (%) SiO2·phosphate (%) SiO2·amino (%) ZrO2·acrylate (%) ZrO2·TODS (%)
Sub-study A
Male animals
 Epididymis 0.706 g = 100 90* 100 106 96 101
 Heart 0.802 g = 100 113 102 111* 108 108
 Spleen 0.454 g = 100 111 119 124* 114 112
Female animals
 Uterus 0.746 g = 100 74 62* 75 74 74
Table 8  Pathology (relative organ weights; expressed as mean of test group (N = 5; except otherwise noted) and relative to respective control 
group)
Relative organ weight: organ weight relative to terminal body weight of the individual animal
Significance, as compared to the control group: * p ≤ 0.5; ** p ≤ 0.1
control group;  
terminal body  
weight (g)
control group;  
organ weight  
















 256 g = 100 % 0.27 Epididymis 82** 93 99 88 96
0.23 Prostate 90 88 90 73* 100
1.19 Testes 89 94 95 90* 99
Female animals
 168 g = 100 % 0.82 Kidneys 94 92* 92** 90** 94
0.23 Thymus 112 93 83* 104 113
control group; terminal  
body weight (g)
control group; organ weight relative  
to terminal body weight
Affected organ SiO2·naked BaSO4
Sub-study B
Male animals
 264 g = 100 % 2.45 liver 111* 108
control group; terminal  
body weight (g)
control group; organ weight relative  
to terminal body weight
Affected organ SiO2·naked (N = 4) BaSO4
Female animals
 176 g = 100 % 0.36 Heart 100 94*
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Gross lesions
For sub-study A, all gross lesions were single observations, 
and they were regarded to have developed spontaneously 
and to be unrelated to either the test compounds or the 
administration procedure.
Sub-study B: One female animal of the SiO2·naked 
test group died ahead of schedule having a thoracic effu-
sion that was assessed as having been caused by a gavage 
error. Therefore, this finding was regarded as related to the 
administration procedure, but not to the test substances. 
All other gross lesions noted were single observations, and 
they were regarded to have developed spontaneously and to 
be unrelated to the test substances or the treatments (data 
not shown).
Histopathology
Sub-study A (Table 9): All findings noted were either single 
observations or they were equally distributed between con-
trol and treatment groups. All of the findings were consid-
ered to be incidental or spontaneous in origin and without 
any relation to the test substance treatment.
Sub-study B (Table 9): In the female animals of the 
BaSO4 test group, minimal to slight inflammatory cell 
infiltrates in the submucosa of the glandular stomach were 
observed. All other findings were either single observations 
or they were equally distributed between the control and 
treatment groups. Therefore, all observations were consid-
ered to be incidental or spontaneous in origin and unrelated 
to the treatment.
Metabolome analysis
At a dose level of 1,000 mg/kg, none of the tested NMs 
had a biologically relevant impact on the plasma metabo-
lome pattern of rats. When compared against the control 
animals on a significance level of p < 0.05, in both male 
and female animals, the number of significantly changed 
endogenous metabolites was below or at the false posi-
tive rate for all particles tested and were assessed as “sta-
tistical variance” of the metabolome analysis (Table 10). 
Using the pattern ranking, i.e., matching the metabolome 
of the compounds with pre-defined patterns of metabolite 
changes, which are associated with adverse effects, there 
were no common, consistent matches with any pattern 
for any of the investigated substances (data not shown).
Discussion
Test substance-related adverse effects were determined for 
none of the seven nanomaterials applied in the 28-day oral 
rat toxicity study, i.e., 4 SiO2·NMs (the core material and 3 
variants with surface functionalization), 2 surface-function-
alized ZrO2 NMs and BaSO4 NM-220, neither in assess-
ing the standard parameters listed in OEcD Tg 407 nor by 
metabolic profiling as a means of detecting changes at very 
early stages of their evolvement (cf. overview in Table 11).
In interpreting the relevance of these observations for 
human safety assessment, a number of issues have to be 
taken into account: (1) Do the physico-chemical charac-
teristics of the nanomaterials in the test substance prepara-
tions reflect those of the same NMs as they would enter the 
human body? Are nanomaterial test substance preparation 
and characterization sufficiently standardized to ensure 
reproducibility of test results in accordance with specified 
parameters? (2) How high is the extent of systemic uptake 
of the tested nanomaterials and the resulting likelihood to 
cause adverse effects outside the gastrointestinal tract?
In the following, these issues are addressed in further 
detail supplemented by a discussion of the results from 
repeated-dose oral toxicity studies and metabolome studies 
investigating NM effects from other research groups.
Nanomaterial preparation and characterization for oral 
studies
It was an important scope of the overall nanogEM pro-
ject, as a part of which the present study was conducted, 
to select surface-functionalized test substances prevailing 
in non-agglomerated conditions in their as-produced state. 
Besides aiming to recognize structure–activity relation-
ships, this served to ensure test result comparability while 
taking into account that dispersion of the NMs in different 
test media would affect their colloidal properties, i.e., their 
state of agglomeration (Wohlleben et al. 2014).
For the oral route of uptake, different NM exposure sce-
narios are foreseeable. As additives to food or feed, NMs 
might (or might not) be transformed (e.g., by dissolution) 
already before ingestion or during digestion (EFSA 2011). 
It has been cautioned that appropriate data for risk assess-
ment of NMs in the food and feed area should include a 
comprehensive identification and characterization of the 
NMs, information on whether they are likely to be ingested 
in nanoform, and, if absorbed, whether they will prevail in 
nanoform during absorption (EFSA 2009). The European 
Food Safety Authority has recommended that NMs in the 
food and feed area should ideally be characterized in five 
stages, i.e., as manufactured, as delivered for use in food 
or feed products, as present in the food and feed matrix, as 
used in toxicity testing, and as present in biological fluids 
and tissues (EFSA 2011).
To date, the specific influences of the various physico-
chemical conditions met during NM passage through the 
gastrointestinal tract on their biokinetic properties are 
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largely unknown making it difficult to predict if and how 
different NMs will be adsorbed (Savolainen et al. 2013). 
Nanoparticle size, surface properties, including charge, and 
dissolution all have been recognized as factors that affect 
NM uptake into the body upon ingestion. NMs reaching 
the gastrointestinal tract are mostly excreted with the feces, 
but for some NMs, low levels of absorption have been 
observed. When such particles become systemically availa-
ble, they might potentially induce systemic effects (lands-
iedel et al. 2012b).
Determination of nanoparticle agglomeration plays a 
major role in assessing the fate of NMs upon oral uptake: 
Since NM adsorption in the gastrointestinal tract decreases 
with increasing particle size, NM agglomeration influ-
ences bioavailability of the original particles. The rate of 
NM agglomeration in different vehicles is affected by the 
pH value of the respective environment (landsiedel et al. 
2012b; Wohlleben et al. 2013).
In the gastrointestinal tract, the intraluminal pH changes 
rapidly from being highly acidic in the stomach to about 
pH 6 in the duodenum from where it gradually increases 
to about pH 7.4 in the terminal ileum (Fallingborg 1999). 
As regards culture media, PBS + BSA has a pH value of 
7.4; DMEM + FcS also has a pH value of 7.4, and it rises 
to 8 after 24 h (supplier information and in-house record-
ings). All test substances of the present study, except 
for SiO2·phosphate, agglomerated in DMEM + FcS. 
In PBS + BSA, especially the NMs of low net charge 
(SiO2·PEg and ZrO2·TODS) formed large agglomerates, 
whereas SiO2·naked remained well dispersed. Since the pH 
of either culture medium resembles the environment of the 
lower small intestine, it is unlikely that the more strongly 
agglomerated NMs undergo significant adsorption in the 
small intestine.
coco et al. (2013) observed polymer coatings to reduce 
pH sensitivity of ovalbumin NMs. PEg-ylated NMs were 
less subject to aggregation due to steric repulsion, and PEg 
chains were found toward the inner surface of the aqueous 
phase containing the albumin. Hence, the PEg barrier was 
able to protect the protein from the denaturing effect of 
organic solvents.
Wohlleben et al. (2013) have found strongly negative 
zeta potentials of NMs, confirmed by iso-electric poten-
tials below pH 4, to correlate with near-perfect dispersion 
in water. At the same time, however, materials with these 
characteristics (e.g., BaSO4 NM-220) were observed to 
agglomerate rather more than less in the presence of serum 
(i.e., DMEM + FcS). By contrast, acrylic acid-copoly-
mer-coated SiO2 was perfectly dispersed in either water 
or culture medium since the polymer corona prevented the 
spontaneous adsorption of a protein corona (Wohlleben 
et al. 2013). Both homogeneous agglomeration (particle–
particle) and heterogeneous agglomeration (particle with 
dissolved organics) contribute to increased diameters. con-
sequently, not only NMs with vanishing charge-stabiliza-
tion due to an iso-electric potential close to the pH of the 
surrounding media, but also positively charged NMs with 
strong corona adsorption can have increased diameters.
The pH value of the medium also affects particle dis-
solution, which is a further important parameter affecting 
NM uptake into the body. Ion release has been recognized 
as correlating with increased NM mobility in the body and 
inflammation potency (Wohlleben et al. 2013). In the acidic 
environment of the stomach, BaSO4 particles dissolve, 
Table 10  Numbers of significantly changed endogenous metabolites in rat plasma (p < 0.05)
Test substance  
(1,000 mg/kg bw/day)
Sex Numbers of up-regulated  
endogenous metabolites
Numbers of down-regulated 
endogenous metabolites
SiO2·PEg Male 7 1
Female 4 7
SiO2·phosphate Male 7 0
Female 4 1
SiO2·amino Male 4 1
Female 11 5
ZrO2·acrylate Male 3 0
Female 3 1
ZrO2·TODS Male 7 1
Female 2 2
SiO2·naked Male 2 11
Female 3 20
BaSO4 Male 4 1
Female 1 4
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whereas SiO2 will partially dissolve already in a neutral 
environment (Wohlleben et al. 2013).
Evidently, also homogeneity of the test substance 
preparations influences NM uptake upon oral delivery. 
Oral NM application by gavage (instead of administra-
tion in the food or drinking water) has been recommended 
as being suitable to ensure well-defined conditions of the 
test substance administration, since it allows delivering a 
fairly precise dose of the NM to the animals by a well-
characterized degree of dispersion (EFSA 2011). Nev-
ertheless, it has been cautioned that NM application by 
gavage does not reflect the lower test substance concentra-
tions delivered over longer periods of time when NMs are 
administered with the animals’ feed: gavage application 
provides a bolus of NMs at a given time point that may 
or may not mix with the gastrointestinal fluids, thereby 
possibly resulting in a higher local NM concentration and 
hence increased quantity of the absorbed material (EFSA 
2011).
Whereas homogeneity of the test substance prepara-
tions was satisfactory in the surface-functionalized SiO2 
and ZrO2 NMs, the non-surface-functionalized SiO2·naked 
and the powder BaSO4 were not distributed homogene-
ously. Suitable standardized protocols remain to be deter-
mined to ensure homogenous distribution of NMs with dif-
ferent surface properties in test substance preparations for 
oral application and to enable determining in which form a 
given NM will reach the different parts of the gastrointesti-
nal tract.
Nanomaterial effects upon repeated oral exposure
Since test substance organ burden was not determined in 
the present study, it is not possible to distinguish whether 
the lack of adverse effects for any of the tested NMs is 
an indication that the test substances did not elicit sys-
temic toxicity even though they were present in relevant 
target organs, or whether they were not taken up into the 
body to a relevant proportion. comparisons of the outcome 
of the present study to other published observations are 
hardly possible: As regards nanoforms of ZrO2 or BaSO4, 
no information on oral repeated-dose toxicity studies was 
found in the published literature. However, also by the 
inhalational route of exposure, in a rat short-term inhala-
tion study (5-day inhalation exposure for 6 h/day with a 
3-week post exposure period) on the identical materials as 
in the present study, neither ZrO2·TODS, nor ZrO2·acrylate, 
or BaSO4 induced any treatment-related effects up to an 
aerosol concentration of 50 mg/m3 (landsiedel et al. 2014). 
Due to its reported lack of toxicity and on account of its 
extensive characterization in the OEcD sponsorship pro-
gramme, BaSO4 was used as ‘negative control’ reference 
material in the present study.
As regards SiO2 NMs, the observation that neither the 
naked core material nor its surface-functionalized variants 
induced treatment-related adverse effects upon repeated 
gavage administration is supported by a 28-day oral toxic-
ity study conducted by van der Zande et al. In this study, 
rats were exposed to 2,500 mg/kg bw/day1 of a commer-
cially available amorphous SiO2 NMs (PPS: 7 nm; in water, 
≥78 % of the material <100 nm (SEM), in feed matrix, 
approximately 40 % was 5–200 nm (IcP–MS)) or to 
1,000 mg/kg SiO2 NM-202 (PPS: 10–25 nm; in water, 
≥61 % <100 nm (SEM), in the feed matrix, approximately 
100 % between 5 and 200 nm). After 28-day oral adminis-
tration, these test substance concentrations did not result in 
distinctly elevated SiO2 levels in the body tissues, and there 
were no observable adverse effects. After 84 days of expo-
sure, however, SiO2 accumulated in the spleen of the rats 
treated with the commercially available amorphous SiO2, 
and a significant increase in the occurrence of liver fibrosis 
was observed in those rats treated with SiO2 NM-202 (van 
der Zande et al. 2014).
By comparison, upon inhalation in a rat STIS 50 mg/m3 
SiO2·naked caused slight and transient increases in granulo-
cyte counts in the blood and increased polymorphonuclear 
neutrophils and lymphocyte counts in the bronchoalveolar 
fluid (BAlF) shortly after exposure and 3 weeks post expo-
sure, whereas there were no discernible effects at lower aer-
osol concentrations. Histologically, multifocal macrophage 
aggregates were observed in the lung shortly after exposure 
that exacerbated toward a slight multifocal inflammation 
after the 3-week exposure-free period. At the same dos-
age, the surface-functionalized SiO2·PEg, SiO2·phosphate, 
and SiO2·amino did not induce adverse effects in the STIS 
(landsiedel et al. 2014).
To date, only few reports on in vivo effects of NMs 
upon subacute or sub-chronic oral exposure are available, 
and hardly any investigations addressed the reversibility 
of effects. The majority of these investigations address the 
effects of silver nanoparticles, some of which also investi-
gated Ag organ burden. Ag NMs have gained commercial 
importance, e.g., in food packaging products, because of 
their antimicrobial activities (Anon 2012; van der Zande 
et al. 2012). In assessing the hazard of silver NMs, the 
extent of particle dissolution has been suggested to be the 
decisive factor determining oral Ag uptake and the severity 
of resulting systemic effects (Hadrup et al. 2012a; Hadrup 
and lam 2014).
Van der Zande et al. (2012) exposed rats orally for 
28 days to 90 mg/kg Ag NMs that were either uncoated 
1
 Note: Except otherwise indicated, all test substance concentrations 
for oral exposure expressed as ‘mg/kg’ refer to mg/kg body weight 
(bw) per day.
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(<20 nm, TEM; 59 nm, DlS) or coated with polyvinylpyr-
rolidone (PVP; <15 nm, TEM; 49 nm, DlS). Immediately 
after the dosing period of either test substance, silver was 
present in all examined organs. The highest levels of NMs 
were recorded in the liver and spleen, but without corre-
sponding signs of hepatotoxicity or immunotoxicity. Sil-
ver concentrations in the organs highly correlated with the 
amount of Ag+ in the Ag NM suspension, indicating that 
mainly silver ions passed the intestines. Eight weeks after 
dosing, silver was cleared from most organs, but not from 
the brain or testis (van der Zande et al. 2012).
Similarly, 9 mg/kg of PVP-coated Ag NMs (14 nm, 
DlS) did not induce any toxicological effects upon 28-day 
oral administration to rats (Hadrup et al. 2012a). For Ag 
acetate, however, (reflecting ionic silver), lower body 
weight gain, increased plasma alkaline phosphatase (AP), 
decreased plasma urea, and lower absolute and relative 
thymus weights were recorded (Hadrup et al. 2012a). Sil-
ver granules containing selenium and sulfur were found in 
the intestinal walls of the rats exposed to either substance 
(loeschner et al. 2011).
In a combined oral repeated-dose—reproduction/devel-
opmental toxicity study performed in accordance with 
OEcD Tg 422 that was conducted for 42 days in male rats 
and for 52 days in female rats, up to 250 mg/kg citrate-
capped Ag NMs (8 nm, TEM; size distribution in deion-
ized water 5–50 nm, submicron particle size analyzer) did 
not affect any of the hematological or clinical biochemistry 
parameters investigated and neither induced histopathologi-
cal changes nor clinically observable effects (Hong et al. 
2014).
Kim et al. (2008) observed changes in AP and choles-
terol at concentrations exceeding 300 mg/kg Ag NMs 
(60 nm; method of particle characterization not indicated) 
when administered orally to rats for 28 days, as well as an 
increase in silver in all tissues examined (with accumula-
tion in the kidneys being twofold higher in females than 
in males). Similar effects were observed upon 90-day oral 
exposure of rats to 30–500 mg/kg Ag NMs (56 nm, TEM; 
Kim et al. 2010). These studies by Kim et al., however, 
have been criticized for insufficient particle characteriza-
tion impairing the value of the test results (Hadrup et al. 
2012a; Dekkers et al. 2013).
In mice exposed orally for 14 days to up to 1.0 mg/kg 
of different Ag NMs (22, 42, 71, and 323 nm, DlS), the 
smaller-sized NMs were distributed to brain, lung, liver, 
kidney, and testis, whereas 323 nm Ag was not. Oral expo-
sure of mice to the same Ag NMs for 28 days (also up to 
1.0 mg/kg) affected the livers and kidneys (determined by 
changes in clinical chemistry parameters and histopathol-
ogy) and increased cytokine levels (Park et al. 2010). Also 
in an in vitro co-culture model of the intestinal epithelium, 
silver ions were found to be the predominant fraction of the 
test substance to translocate across the epithelium (Bouw-
meester et al. 2011).
Apart from Ag NMs, a number of further metal and 
metal oxide NMs have been studied in repeated-dose oral 
toxicity studies: At 537 mg/kg, zinc oxide NMs (40 nm, 
TEM and SEM; 202 nm, photon correlation spectroscopy), 
administered orally to rats for 90 days, resulted in anemia-
related hematological changes, mild to moderate pancrea-
titis, and, in the male rats, reduced weight gain (Seok et al. 
2013). In mice, 14-day oral exposure to 300 mg/kg ZnO 
NMs (30 nm, TEM; 272 nm, DlS) resulted in liver dam-
age (determined by clinical chemistry and histopathology) 
and DNA damages in the liver and kidney (determined by 
comet assay; Sharma et al. 2012).
At 1,000 mg/kg, 28-day oral exposure of Fe2O3 NMs 
(30 nm, TEM; 363 nm, DlS and laser Doppler Veloci-
metry) induced damages of the liver and kidneys in rats, 
as observed by histopathology and clinical chemistry. Fur-
thermore, synaptic transmission and nerve conduction were 
affected in the animals’ brains, however, without corre-
sponding histopathological changes (Kumari et al. 2012). 
Upon 28-day oral exposure, 300 and 1,000 mg/kg man-
ganese oxide NMs (43 nm, TEM; 325 nm, DlS) induced 
genetic damage in the leukocytes and bone marrow of rats, 
and alterations in liver, spleen, kidney, and brain (deter-
mined by histopathology and clinical chemistry; Singh 
et al. 2013).
In rats, 5-day oral exposure to 50–200 mg/kg copper 
NMs (primary size: 25 nm; size distribution 5–60 nm, DlS 
and atomic force microscopy) resulted in widespread renal 
proximal tubule necrosis (liao and liu 2012). In mice, 
14-day oral exposure to 20 mg/kg ‘biogenic’ (i.e., produced 
by Bacillus sp.) selenium NMs (105–130 nm, TEM; no 
characterization of prepared test substance) caused lower 
body weight and changes in hematological parameters and 
clinical chemistry (Shakibaie et al. 2013).
Five-day oral exposure of rats to 1 or 2 mg/kg anatase 
TiO2 NMs (<25 nm, TEM; agglomeration up to 1.6 µm, 
SEM) induced histological alterations in female animals 
in the spleen, thyroid, adrenal medulla, adrenal cortex, and 
ovarian granulosa, albeit without corresponding clinical 
signs of toxicity. In male rats, thyroid function was altered 
and testosterone levels were increased in the high-dose 
group (Tassinari et al. 2014). Bu et al. (2010) exposed rats 
orally to 1 g/kg rutile-anatase TiO2 NMs (<50 nm, xRD; 
no information on hydrodynamic particle diameter) for 14 
consecutive days and observed disturbances in the amino 
acid and energy metabolisms, in the gut microflora environ-
ment, as well as slight injury to the heart and liver tissues.
To date, in vivo studies comparing the effects of differ-
ent nanomaterials under identical experimental conditions 
or assessing organ burden upon oral NM administration are 
scarce. An exception is the study by cho et al. (2013) who 
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exposed rats orally to 260–1,042 mg/kg TiO2 (80 % anatase, 
20 % rutile; 26 nm, SEM, 38 nm, DlS) or 134–536 mg/
kg ZnO NMs (90 nm, SEM; 202 nm, DlS) for 13 weeks 
(7 days/week). Ti or Zn organ tissue burden was assessed 
upon necropsy revealing that TiO2 nanoparticles were not 
significantly increased in sampled organs, even in the group 
receiving the highest dose (1,042 mg/kg). By contrast, Zn 
concentrations in the liver and kidney were significantly 
increased, and minimally increased in the spleen and brain, 
as compared to the vehicle controls (cho et al. 2013).
In regard to carbon-based NMs, there were no treat-
ment-related effects in rats upon 28-day oral exposure to 
12.5 mg/kg single-walled carbon nanotubes (SWcNTs; 
basic morphology sheet form consisting of entangled 
cNTs, diameter 2 nm) or 50 mg/kg multi-walled car-
bon nanotubes (MWcNTs; basic morphology entangled 
cNTs, diameter 30 nm; Matsumoto et al. 2012). Neverthe-
less, Matsumoto et al. conclude that, due to cNT absorp-
tion and persistence, longer-term effects of these materials 
cannot be excluded. Finally, upon 29-day oral exposure to 
1,000 mg/kg fullerene C60 (0.71 nm diameter; no further 
characterization), liver and spleen weights were slightly 
increased in rats without corresponding signs of toxicity 
(Takahashi et al. 2012).
In summary, reports on repeated-dose oral toxicity 
studies investigating NM effects are scarce. Oftentimes, 
they were not conducted in accordance with standardized 
test guidelines, or the test substances were not submitted 
to comprehensive characterization in the prepared states. 
Furthermore, comparative hazard assessments of different 
NMs under identical experimental conditions are lacking, 
just as investigations on the reversibility or progression of 
effects. Many effects were observed by histopathological 
examination or clinical chemistry, but were not accom-
panied by corresponding clinical findings. Therefore, it 
is oftentimes difficult, if not impossible, to determine the 
relevance such adverse effects, and it is not yet possible 
to come to a conclusion in regard to, e.g., ranking of toxic 
effects of different types of NMs upon subacute or sub-
chronic oral exposure. Of note, however, of the seven NMs 
tested in the present study, only SiO2·naked elicited adverse 
effects upon 5-day inhalation, but only locally in the lungs, 
and this effect was only observed at the highest test sub-
stance concentration. Since inhalation is the most important 
route of exposure for NMs, these findings corroborate the 
assumption that the tested NMs do not elicit substantial 
adverse effects upon the experimental conditions applied in 
the present study.
Metabolome analysis
likewise, under the conditions of the present study, the 
seven SiO2, ZrO2, and BaSO4 NMs did not affect the 
plasma metabolome in female or male rats. In accordance 
with the criteria defined by EcETOc to determine adverse 
effects based on ‘-omics’ data (EcETOc 2008, 2010, 
2013) and since there were no matches with the specific 
toxicity patterns of the MetaMap®Tox database, the dose 
level tested, i.e., 1,000 mg/kg, can be considered as metab-
olomic no-observed-adverse-effect level (NOAEl) upon 
oral 28-day exposure to rats. Furthermore, the number of 
significant endogenous metabolite changes was below or 
at the false positive rate for all treatments in both sexes. 
Therefore, the dose level of 1,000 mg/kg can also be con-
sidered as a metabolomic no-observed-effect level (NOEl).
To date, only few studies have performed metabolic pro-
filing of NM effects (Schnackenberg et al. 2012). There 
was no metabolomics study reports to be found in the peer-
reviewed literature allowing comparing the results of the 
present study to those from similar investigations. Those 
NM metabolomics studies retrieved not only investigated 
different types of NMs, which sometimes further were not 
submitted to a thorough physico-chemical characterization. 
These studies also applied different forms of test substance 
administration and evaluated different tissues or body flu-
ids in mice or rats by different technologies and procedures 
for metabolic profiling. In this context, lc–MS/MS and 
gc–MS techniques have been assessed as being more sen-
sitive than nuclear magnetic resonance (NMR) techniques, 
thereby increasing the likelihood of detecting relevant bio-
markers or patterns of change (van Ravenzwaay et al. 2007; 
Schnackenberg et al. 2012). A further issue to be taken into 
account in assessing the relevance of metabolomics stud-
ies is the statistical procedure applied in analyzing changes 
in metabolite patterns (EcETOc, 2008, 2010; Schnacken-
berg et al. 2012). All of these differences in testing schemes 
make the results of currently available metabolomics stud-
ies difficult, if not impossible to compare.
In the liver tissues and serum of mice that were killed 
3 h after intravenous injection of SiO2 NMs (30, 70, and 
300 nm; DlS), changes in metabolite patterns were revealed 
by gc–MS combined with pattern recognition approaches, 
indicating disturbances in energy metabolism as well as 
amino, lipid, and nucleotide metabolism, which were con-
sidered attributable to hepatotoxicity (lu et al. 2011).
Applying 150 µg amorphous SiO2 NMs (10 and 80 nm, 
TEM; no secondary particle characterization) by intranasal 
instillation into both nostrils of rats for 90 days, the metab-
olomic profile of the serum, determined by NMR, exhibited 
significantly increased lactate, alanine, acetate, creatine, 
and choline coupled with a considerable decrease in the 
glucose level (Parveen et al. 2012). Parveen et al. conclude 
that these observations implicate an impairment of the tri-
carboxylic acid cycle and liver metabolism, suggesting that 
SiO2 NMs may potentially induce hepatotoxicity in rats 
upon sub-chronic administration.
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In an in vitro study with human MRC-5 fetal lung fibro-
blasts treated with up to 80.0 μg ml SiO2 NMs (average 
diameter 45 nm; no indication of secondary particle char-
acterization), Huang et al. (2012) recorded dose-dependent 
decreases of various cellular amino acid levels as well as 
glutathione accompanied with increased phospholipid and 
urea concentrations (making use of gc–MS and lc–MS). 
However, there was no evidence of morphological or cell 
viability changes (as determined by light microscopy and 
in a tetrazolium reduction assay; Huang et al. 2012).
In the urine and serum of rats exposed orally to 1 g/
kg rutile-anatase TiO2 NMs (<50 nm, xRD; no informa-
tion on hydrodynamic particle diameter) for 14 days, Bu 
et al. (2010) observed metabolite changes indicating dis-
turbances in the energy and amino acid metabolism by 
NMR using principal components and partial least squares 
discriminant analysis. After intratracheal instillation of 
rats to 0.8–20 mg/kg TiO2 (5 nm; TEM, no indication of 
secondary particle characterization), urine metabolite 
changes reflecting acute, transient metabolic disturbances 
of the liver and kidneys were only observed in the low-dose 
groups (Tang et al. 2010). These changes were not paral-
leled by histopathological or serum biochemical altera-
tions, whereas at higher dosages, the TiO2 NMs provoked 
histopathological pulmonary inflammatory responses. Tang 
and co-authors conclude that at low dosages, TiO2 NMs 
can enter the blood circulation, whereas at higher dosages, 
the particles tend to agglomerate and accumulate in the 
lung (Tang et al. 2010).
Hadrup et al. (2012b) applied high performance liquid 
chromatography–quadrupole time-of-flight mass spec-
trometry (HPlc–QTOF–MS) and principal component 
analysis (PcA) to determine rat urine metabolite patterns 
after 18-day oral exposure of up to 9.0 mg/kg PVP-coated 
Ag NMs (14 nm; DlS). Thereby, Hadrup et al. observed 
metabolomic differences in the urine from female, but not 
male rats. Metabolomic differences between male and 
females have been described before (van Ravenzwaay et al. 
2007). Administration of nanoform silver increased both 
uric acid and its degradation product allantoin, suggesting 
that purine metabolism was affected (Hadrup et al. 2012b).
Feng et al. (2010) investigated the metabolic responses 
induced by 25 mmol/l of uncoated and dextran-coated 
ultra-small superparamagnetic iron oxide (2.3–4 nm; hydro-
dynamic particle size: 20 nm; no indication of characteri-
zation methodology) upon intravenous injection into rats. 
Applying NMR-based analysis in combination with mul-
tivariate statistical analysis of both rat urine and plasma 
metabolomes, Feng and co-authors observed size- and sur-
face chemistry-dependent changes in energy, lipid, glucose, 
and amino acid metabolic pathways that may be attributed 
to disturbances of hepatic, renal, and cardiac functions.
Conclusion
Under the experimental conditions of the present study, 
neither the 4 SiO2 NMs (the core material and its 3 vari-
ants with different surface functionalizations), nor the 2 
surface-functionalized ZrO2 NMs or BaSO4 NM-220, elic-
ited any effects upon 28-day oral exposure to rats that were 
assessed as test substance-related and adverse. Similarly, 
apart from the core SiO2·naked also none of the test materi-
als induced adverse effects upon 5-day inhalation exposure 
to rats (landsiedel et al. 2014). These findings—together 
with the lack of changes in metabolite patterns recorded 
in the present study—suggest that the tested substances do 
not elicit systemic toxicity under the reported experimental 
conditions. Further investigations, however, are necessary 
to develop and assess standardized procedures for test sub-
stance preparation for oral administration ensuring reliable 
substance homogeneity. likewise, further investigations 
should aim at determining the amount of NM that can enter 
the body upon ingestion under different experimental con-
ditions taking into account a variety of different test sub-
stance preparations.
To date, only a limited number of subacute and sub-
chronic toxicity studies investigating NM effects upon oral 
exposure are available, and the variety of different NMs as 
well as of different testing protocols applied makes it diffi-
cult to compare the outcome of different studies. Due to the 
diversity and complexity of different types of NMs, several 
authors have highlighted that conducting repeated-dose 
toxicity studies in rodents for every new NM introduced 
onto the market is impractical, if not impossible (lai 2012; 
Nel et al. 2013; Oomen et al. 2014). Therefore, further 
work should also aim at making use of the data collected 
so far to develop and implement concern-driven integrated 
strategies for the testing and assessment of nanomaterials 
taking into account realistic exposure scenarios (lai 2012; 
Nel et al. 2013; Oomen et al. 2014).
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